Politics

Donald Trump’s realty firm is representing one of the country’s largest pharmaceutical companies in its effort to offload a $12 million New York condo—an arrangement that represents yet another apparent conflict of interest for the 47th president of the United States.

The condo on the 39th floor of the Trump International Hotel and Tower at Columbus Circle has been on and off the market for several years but hasn’t been successfully sold. According to real estate websites, it was listed by a different realty firm, Sotheby’s, until late last month. Around that time, it was listed for sale on Trump International Realty’s website. If it sells at its current listing price, it would likely earn hundreds of thousands of dollars in commissions for Trump’s firm.

According to New York real estate records, the Swiss pharmaceutical giant Roche bought the swanky 3,000-square-foot condo back in 2006. The two-bedroom unit features “sweeping views of Central Park,” along with “lacquered custom tray ceilings with custom lighting, custom pocket doors, Steinway black lacquered doors, Corian counters, subzero refrigerator, Wolf convection oven, wine cooler and marble bath.” It’s unclear why Roche—which has offices across the United States—originally purchased the property or why it recently turned to Trump’s real estate firm for help. Roche and its American biotech subsidiary, Genentech, did not respond to requests for comment. Nor did the Trump Organization or Karina Lynch, an attorney with the powerhouse firm DLA Piper, who was recently announced as the Trump Organization’s “outside ethics adviser.”